Counseling Patients on Side Effects and Driving When Starting Opioids #248

Randall E. Schisler, M.D., Hunter Groninger, M.D., and Drew A. Rosielle, M.D.

Background

Opioids have side effects that can limit their acceptability to patients. This *Fast Fact* gives expert opinion recommendations about patient counseling when initiating opioid therapy. See *Fast Fact* #83 for a discussion of patient fear of opioids, including addiction and tolerance.

Key Symptoms

Patients should be reassured that most opioid side effects are short-lived or otherwise manageable, and they should seek help immediately for intolerable side effects.

• Constipation

- *Background for clinicians:* Very common, reported by 23% to 84% of patients in various studies. It does not diminish over time, even on a steady dose. Opioids delay gastric emptying, decrease peristalsis, decrease secretions, and slow small bowel transit time.¹
- *Key counseling points:*
 - Most patients need an ongoing bowel regimen involving stimulant laxatives (stool softeners such as docusate or bulking agents like fiber are ineffective), which should be used as maintenance therapy to *prevent* constipation, not just rescue therapy to *treat* it after it has developed.¹
 - Patients should aim for an unstrained bowel movement at least every other day. “If you have not had a bowel movement in 4 days, call me for advice.”

• Nausea

- *Background for clinicians:* Nausea occurs in approximately 25% of patients given opioids.² There are many effective strategies to prevent and ameliorate opioid-induced nausea – see *Fast Fact* #25 for more details. Make sure patients have access to your anti-emetic of choice. There is no consensus as to whether

anti-emetics should be given prophylactically when initiating or increasing opioids.

○ *Key counseling points:*

- Nausea is usually transient and resolves in several days on a stable dose.³
- Patients should use their prescribed anti-emetic if nausea develops, but should contact you immediately if it is ineffective and/or vomiting occurs so you can prescribe alternative agents.

• Sedation (See also the section on driving below.)

- *Background for clinicians:* Sedation occurs in 20% to 60% of patients,² usually during opioid initiation or around the time of dose increases. Mild-to-moderate sedation usually resolves in a few days; if persistent, it may improve with drug therapy.⁴ Moderate-to-severe sedation responds to dose reduction, but may also necessitate opioid rotation.
- *Key counseling points:*
 - Reassure patients that mild-to-moderate sedation usually resolves in a few days.
 - Encourage patients to accept mild sedation (eg, noticeable drowsiness, falling asleep unintentionally during relaxing activities, such as watching TV or reading) for a few days as long as they are in a safe environment. Moderate (falling asleep during stimulating activities such as eating or having a conversation) or severe sedation should prompt a call to you immediately to discuss next steps.

Less Common Symptoms

- Pruritus is rare and does not require extensive pre-emptive counseling. “If you feel itchy, it might go away after a few days. If it’s really bothering you or not going away, call me and we can make some changes.” See *Fast Fact* #37.

Fast Facts and Concepts are edited by Drew A Rosielle MD, Palliative Care Program, University of Minnesota Medical School and Fairview Health Services, and are published by the End of Life/Palliative Education Resource Center at the Medical College of Wisconsin. For more information write to: drosiel1@fairview.org. More information, as well as the complete set of *Fast Facts*, are available at EPERC: <http://www.mcw.edu/eperc>.

Copyright/Referencing Information: Users are free to download and distribute *Fast Facts* for educational purposes only. Available at: http://www.eperc.mcw.edu/fastfact/ff_248.htm.

Disclaimer: *Fast Facts and Concepts* provide educational information. This information is not medical advice. Health care providers should exercise their own independent clinical judgment. Some *Fast Facts* cite the use of a product in a dosage, for an indication, or in a manner other than that recommended in the product labeling. Accordingly, the official prescribing information should be consulted before any such product is used.

- Urinary retention is rare but potentially an emergency. Counsel patients to seek medical care immediately if they lose the ability to urinate.

Driving Safety

There are no large, randomized studies directly examining the risk of driving while on opioids.⁶ Opioids can slow reaction time, cause drowsiness, or cloud judgment when they are first started or increased.⁷ Most experts agree that driving or operating heavy machinery is unsafe and should be avoided until a stable dose has been reached.⁸ Multiple smaller studies suggest that many patients on chronic opioids (defined as no dose change within the last week) have no increased risk of motor vehicle collisions compared with the general population and no reduction in concentration or perception compared with control subjects.⁹ According to one study, which videotaped patients while actually driving, those on chronic opioid therapy versus healthy controls displayed neither a difference in driving errors in community or obstacle course driving, nor in tests of attention.¹⁰

Counseling bottom line: Patients who have been on a stable dose for a week, who feel no cognitive changes (drowsiness, fuzziness, difficulties in concentrating) can drive.

For commercial driving, the Federal Motor Carriers Safety Administration generally prohibits opioid use, but with the caveat that these rules, “do not apply to the possession or use of a substance administered to a driver by or under the instructions of a licensed medical practitioner...who has advised the driver that the substance will not affect the driver’s ability to safely operate a motor vehicle.”¹¹ Individual states, employers, and insurance agencies may have further restrictions, and patients should be advised to investigate these before driving commercially.

References

1. McMillan SC: Assessing and managing opiate-induced constipation in adults with cancer. *Cancer Control* 2004; 11(3):3–9.
2. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S: Symptoms during cancer pain treatment following WHO-guidelines: A longitudinal follow-up study of symptom prevalence, severity and etiology. *Pain* 2001;93:247–257.
3. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V; Expert Working Group of the European Association of Palliative Care Network: Strategies to manage the adverse effects of oral morphine: an evidence-based report. *J Clin Oncol* 2001;19:2542–2554.
4. Bruera E, Miller MJ, Macmillian K, Kuehn N: Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. *Pain* 1992;48(2):163–166.
5. Kjellberg F, Tramer MR: Pharmacological control of opioid-induced pruritus: A quantitative systematic review of randomized trials. *Eur J Anesth* 2001;18(6):346–357.
6. Chapman S: The effects of opioids on driving ability in patients with chronic pain. *Bull Am Pain Soc* 2001;11:1.
7. Galski T, Williams JB, Ehle HT: Effects of opioids on driving ability. *J Pain Symptom Manage* 2000;19(3):200–208.
8. *Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain*. National Opioid Use Guideline Group. April 30, 2010. Available at: www.nationalpaincentre.mcmaster.ca/opioid/documents.html. (Last accessed June 2011).
9. Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS: Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. *J Pain Symptom Manage* 2003;25(6):559–577.
10. Byas-Smith MG, Chapman SL, Reed B, Cotsonis G: The effect of opioids on driving and psycho-motor performance in patients with chronic pain. *Clin J Pain* 2005;21(4):345–352.
11. *Drugs and Other Substances*. US Department of Transportation Federal Motor Carrier Safety Administration Rules & Regulations. Available at: www.fmcsa.dot.gov/rulesregulations/administration/fmcsr/fmcsrruletext.aspx?reg=392.4. (Last accessed May 2011).

Address correspondence to:
Hunter Groninger, M.D.
Pain and Palliative Care Service
Clinical Center
Building 10, Room 2-1733
National Institutes of Health
Bethesda, MD 20892

E-mail: hunter.groninger@nih.gov

DOI: 10.1089/jpm.2012.9597

Borderline Personality Disorder in Palliative Care #252

Laura McLafferty, M.D. and Julie W. Childers, M.D.

Background

Borderline personality disorder (BPD) is identified by a pervasive pattern of instability of relationships, self-image,

and mood, as well as marked impulsivity.¹ The prevalence of BPD in the general population is 1% to 2%, and, despite the impression of a female predominance, evidence indicates that it occurs equally frequently in men and women.² The stresses